LatestSixth in Series: 9/11 Coverage Had Greater Impact Than Mameyes Disaster
Cannabis

Federal Appeals Court Sets Timeline for Hemp and CBD Medicare Coverage Litigation

Raúl del Pino
Summary

A federal appeals court has established a litigation schedule for a significant case challenging the exclusion of hemp-derived cannabidiol (CBD) products from Medicare coverage in the United States. This legal development could have substantial implications for Medicare beneficiaries seeking access to CBD and hemp-based therapeutic products for various health conditions. The case addresses whether federally legal hemp and CBD products should be covered under Medicare's pharmaceutical benefits, potentially expanding treatment options for eligible patients. The established timeline will determine when arguments will be heard and decisions rendered on this important healthcare access issue.

Originally published on

Cannabis Magazine

By Raúl del Pino

Read full article(opens in new tab)

Fetched: August 28, 2026 at 10:02 AM

Related News

More news you might be interested in

View all
Chilean Documentary Exposes Pinochet-Era Biochemist's Role in Neurotoxins and Cocaine Trafficking
Cannabis

Chilean Documentary Exposes Pinochet-Era Biochemist's Role in Neurotoxins and Cocaine Trafficking

The Chilean documentary 'Cocaína Negra' investigates Eugenio Berríos, a biochemist connected to Augusto Pinochet's secret police, through newly uncovered recordings. The film documents his involvement in manufacturing neurotoxic agents, clandestine dictatorship networks, and decades-long accusations linking him and superiors to cocaine trafficking operations. This historical investigation reveals the intersection of state-sponsored chemical weapons development and organized drug trafficking during Chile's authoritarian regime. The documentary provides critical context on how scientific expertise was weaponized for political repression.

17 hours ago
Revista Cáñamo
France Reports 500 Synthetic Cannabinoid Exposures Since 2025
Cannabis
AnxietySchizophrenia

France Reports 500 Synthetic Cannabinoid Exposures Since 2025

France has documented approximately 500 exposure cases to synthetic cannabinoids since 2025, prompting authorities to strengthen surveillance measures in 2026. Over 70% of cases affected adolescents aged 13-18 years, with 71% classified as severe exposures. Health officials warn that the actual composition of these products often differs significantly from their labels, posing substantial risks to young users. Synthetic cannabinoids are far more potent than natural cannabis and carry serious health consequences including rapid heart rate, severe anxiety, and psychotic episodes. This outbreak underscores the dangers of unregulated substances and the critical need for public awareness among Puerto Rican youth and parents.

17 hours ago
Revista Cáñamo
MJBizDaily
Cannabis

Arizona Cannabis Operator Closes Ohio Store Amid State Investigation of Serious Health Events

An Arizona-based multistate cannabis operator voluntarily closed one of its Ohio retail locations after state regulators launched an investigation into at least two serious adverse health events reportedly linked to customers. The voluntary closure demonstrates the operator's commitment to patient safety and regulatory compliance while authorities investigate the nature and cause of the health incidents. This action highlights the critical importance of product quality control, testing protocols, and consumer safety measures within the regulated cannabis industry. The investigation underscores ongoing regulatory scrutiny of cannabis products and the need for transparent reporting of adverse events to protect public health.

18 hours ago
MJBizDaily
MJBizDaily
Cannabis

Delaware Cannabis Sales Hit Record in July, Fall Short of Projections

Delaware's cannabis market reached record sales in July, yet performance trails state projections due to regulatory hurdles. Licensing delays have prevented retail-only stores from launching, limiting consumer access and product selection. High prices and restricted inventory are driving patients and consumers to purchase from neighboring states, undermining the local market's growth potential. These regulatory and market challenges highlight the importance of streamlined licensing processes and competitive pricing for medical cannabis patients seeking accessible treatment options.

20 hours ago
MJBizDaily